

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/644,579-Conf. #5200
				Filing Date	August 20, 2003
				First Named Inventor	Connie Sanchez
				Art Unit	1617
				Examiner Name	Y. S. Chong
Sheet	1	of	1	Attorney Docket Number	05432/100M919-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Mischoulon et al., "Strategies for Managing Depression Refractory to Selective Serotonin Reuptake Inhibitor Treatment: A Survey of Clinicians", Can. J. Psychiatry, 45, 476-481 (2000)	
	CB	Posternak et al., "Switching Versus Augmentation: A prospective, Naturalistic Comparison in Depressed, Treatment-Resistant Patients", J. Clin Psychiatry, 62, 135-142 (2001)	
	CC	Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Depression by the Committee for Proprietary medicinal Products (CPMP) Dated April 25, 2002	
	CD	Approval Package of the Center for Drug Evaluation and Research for Citalopram Hydrobromide (trade name: Celexa) dated July 17, 1998 including the Approval Letter, the Approvable Letter and the Final Printed Labelling specification, said documents having been made available to the public by the FDA on July 20, 1998.	
	CE	Merck Manual of Diagnostics, Home Edition, pp 438-447 (1997).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.